Okyo Pharma Limited ADR (OKYO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,970 | -16,803 | -13,284 | -6,218 | -3,379 |
| Depreciation Amortization | 3 | 4 | 4 | 2 | 2 |
| Accounts payable and accrued liabilities | 1,216 | 2,799 | N/A | -298 | 886 |
| Other Working Capital | 1,627 | 2,670 | 3,946 | -1,024 | 1,045 |
| Other Operating Activity | 3,314 | 1,840 | 1,639 | 2,069 | -154 |
| Operating Cash Flow | $-1,811 | $-9,491 | $-7,695 | $-5,468 | $-1,600 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1 | N/A | -6 | -2 | -7 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -11 |
| Investing Cash Flow | $-1 | $N/A | $-6 | $-2 | $-18 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 950 | N/A | 2,000 | N/A | 7,593 |
| Common Stock Issued | 1,706 | 6,209 | 7,323 | 2,153 | 246 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -12 |
| Financing Cash Flow | $2,656 | $6,209 | $9,323 | $2,153 | $7,827 |
| Exchange Rate Effect | -110 | 64 | -278 | -872 | 445 |
| Beginning Cash Position | 827 | 4,045 | 2,701 | 6,889 | 236 |
| End Cash Position | 1,561 | 827 | 4,045 | 2,701 | 6,889 |
| Net Cash Flow | $734 | $-3,219 | $1,345 | $-4,189 | $6,654 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,811 | -9,491 | -7,695 | -5,468 | -1,600 |
| Capital Expenditure | -1 | N/A | -6 | -2 | -7 |
| Free Cash Flow | -1,812 | -9,491 | -7,701 | -5,470 | -1,607 |